WALTHAM, Mass., March 12, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) welcomed today an announcement by La Jolla Pharmaceutical Company (LJPC) on March 10, 2014 of positive top-line results of its randomized, placebo-controlled Phase 2 trial of the galectin-3 inhibitor compound GCS-100 in chronic kidney disease. The trial met its primary efficacy endpoint of improvement in kidney function, as well as key secondary endpoints including a statistically significant reduction in circulating levels of galectin-3, the molecular target of GCS-100, at the effective therapeutic dose, as measured using the BGM Galectin-3 ® Test.
BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement Of Positive Top-Line Results Of Phase 2 Clinical Trial Of Novel Pharmaceutical Compound Targeting Galectin-3 In Chronic Kidney Disease
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts